Exploring the pharmacological mechanism of Yanghe Decoction on HER2-positive breast cancer by a network pharmacology approach

Journal of Ethnopharmacology

Volumn 199, Issue , 2017, Pages 68-85

  Zeng, Liuting ^a   Yang, Kailin ^a  

^a HUNAN UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Chinese medicine formulae; HER2 positive breast cancer; Network pharmacology; Traditional Chinese medicine; Yanghe Decoction

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; ESTROGEN; GLABRIDIN; HERBACEOUS AGENT; KAEMPFEROL; LUTEOLIN; NARINGENIN; PROGESTERONE; QUERCETIN; STEROID HORMONE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; YANGHE DECOCTION; ERBB2 PROTEIN, HUMAN; YANGHE;

ARTICLE; BREAST CANCER; CACO-2 CELL LINE; CHINESE MEDICINE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG SCREENING; FEASIBILITY STUDY; GENE INTERACTION; GENOMICS; HUMAN; MATHEMATICAL MODEL; MOLECULAR BIOLOGY; NONHUMAN; PROTEIN PROTEIN INTERACTION; TUMOR GENE; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; GENE REGULATORY NETWORK; GENETICS;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CACO-2 CELLS; DRUGS, CHINESE HERBAL; FEMALE; GENE REGULATORY NETWORKS; HUMANS; RECEPTOR, ERBB-2;

EID: 85012295326     PISSN: 03788741     EISSN: 18727573     Source Type: Journal    
DOI: 10.1016/j.jep.2017.01.045     Document Type: Article

References (122)

1. Achen, M.G., Williams, R.A., Baldwin, M.E., Lai, P., Roufail, S., Alitalo, K., Stacker, S.A., The angiogenic an lymphangiogenic factor vascularendothelial growth factor-D exhibits a paracrine mode of action in cancer. Growth Factors 20 (2002), 99–107.
2. Akahane, M., Akahane, T., Matheny, S.L., Shah, A., Okajima, E., Thorgeirsson, U.P., Vascular endothelial growth factor-D is a survival factor for human breast carcinoma cells. Int. J. Cancer 118 (2006), 841–849.
3. Ano, R., Kimura, Y., Shima, M., Matsuno, R., Ueno, T., Akamatsu, M., Relationships between structure and high-throughput screening permeability of peptide derivatives and related compounds with artificial membranes: application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 12 (2004), 257–264.
4. Azuma, H., Ehata, S., Miyazaki, H., Watabe, T., Maruyama, O., Imamura, T., Sakamoto, T., Kiyama, S., Kiyama, Y., Ubai, T., Inamoto, T., Takahara, S., Itoh, Y., Otsuki, Y., Katsuoka, Y., Miyazono, K., Horie, S., Effect of Smad7 expression on metastasis of mouse mammary carcinoma JygMC (A) cells. J. Natl. Cancer Inst. 97 (2005), 1734–1746.
5. Bader, G.D., Hogue, C.W., An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinform., 4, 2003, 2.
6. Banerji, S., Cibulskis, K., Rangel-Escareno, C., Brown, K.K., Carter, S.L., Frederick, A.M., Lawrence, M.S., Sivachenko, A.Y., Sougnez, C., Zou, L., Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486 (2012), 405–409, 10.1038/nature11154.
7. Barabási, A.L., Gulbahce, N., Loscalzo, J., Network medicine: a network-based approach to human disease. Nat. Rev. Genet. 12 (2011), 56–68, 10.1038/nrg2918.
8. Benatar, T., Yang, W., Amemiya, Y., Evdokimova, V., Kahn, H., Holloway, C., Seth, A., IGFBP7 reduces breasttumor growth by induction of senescence and apoptosis pathways. Breast Cancer Res. Treat. 133 (2012), 563–573, 10.1007/s10549-011-1816-4.
9. Blanco, M.A., Kang, Y., Signaling pathways in breast cancer metastasis - novel insights from functional genomics. Breast Cancer Res., 13, 2011, 206, 10.1186/bcr2831.
10. Borowiec, A.S., Hague, F., Gouilleux-Gruart, V., Lassoued, K., Ouadid-Ahidouch, H., Regulation of IGF-1-dependent cyclin D1 and E expression by hEag1 channels in MCF-7 cells: the critical role of hEag1 channels in G1 phase progression. Biochim. Biophys. Acta 1813 (2011), 723–730, 10.1016/j.bbamcr.2011.01.025.
11. Carboni, J.M., Lee, A.V., Hadsell, D.L., Rowley, B.R., Lee, F.Y., Bol, D.K., Camuso, A.E., Gottardis, M., Greer, A.F., Ho, C.P., Hurlburt, W., Li, A., Saulnier, M., Velaparthi, U., Wang, C., Wen, M.L., Westhouse, R.A., Wittman, M., Zimmermann, K., Rupnow, B.A., Wong, T.W., Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res. 65 (2005), 3781–3787.
12. Castoria, G., Migliaccio, A., Bilancio, A., Di Domenico, M., de Falco, A., Lombardi, M., Fiorentino, R., Varricchio, L., Barone, M.V., Auricchio, F., PI3-kinase in concert with Src promotes the S-phase entry of estradiol stimulated MCF-7 cells. EMBO J. 20 (2001), 6050–6059.
13. Chandrika, B.B., Steephan, M., Kumar, T.R., Sabu, A., Haridas, M., Hesperetin and Naringenin sensitize HER2 positive cancer cells to death by serving as HER2 Tyrosine Kinase inhibitors. Life Sci. 160 (2016), 47–56, 10.1016/j.lfs.2016.07.007.
14. Chen, F.P., Chang, C.M., Hwang, S.J., Chen, Y.C., Chen, F.J., Chinese herbal prescriptions for osteoarthritis inTaiwan: analysis of National health insurance dataset. BMC Compl. Altern. Med., 14, 2014, 91.
15. Chen, J., Zeng, J., Xin, M., Huang, W., Chen, X., Formononetin induces cell cycle arrest of human breast cancer cells via IGF1/PI3K/Akt pathways in vitro and in vivo. Horm. Metab. Res. 43 (2011), 681–686, 10.1055/s-0031-1286306.
16. Chiu, C.G., Masoudi, H., Leung, S., Voduc, D.K., Gilks, B., Huntsman, D.G., Wiseman, S.M., HER-3 overexpression is prognostic of reduced breast cancer survival: a study of 4046 patients. Ann. Surg. 251 (2010), 1107–1116, 10.1097/SLA.0b013e3181dbb77e.
17. Cook, M.T., Liang, Y., Besch-Williford, C., Goyette, S., Mafuvadze, B., Hyder, S.M., Luteolin inhibits progestin-dependent angiogenesis, stem cell-like characteristics, and growth of human breast cancer xenografts. Springerplus, 4, 2015, 444, 10.1186/s40064-015-1242-x (eCollection 2015).
18. Deckers, M., van Dinther, M., Buijs, J., Que, I., Löwik, C., van der Pluijm, G., ten Dijke, P., The tumor suppressor Smad4 is required for transforming growth factor β-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res. 66 (2006), 2202–2209.
19. Dickson, R.B., Stancel, G.M., Estrogen receptor-mediated processes in normal and cancer cells. J. Natl. Cancer Inst. Monogr. 27 (2000), 135–145.
20. Dong, S., Inoue, A., Zhu, Y., Tanji, M., Kiyama, R., Activation of rapid signaling pathways and the subsequent transcriptional regulation for the proliferation of breast cancer MCF-7 cells by the treatment with an extract of Glycyrrhiza glabra root. Food Chem. Toxicol. 45 (2007), 2470–2478.
21. Dou, J.W., Hao, Y., Yang, Y.Q., Zhu, J., You, F.M., The exposition of the theory on Yanghe Decoction treating breast cancer. World Chin. Med. 02 (2015), 196–198.
22. Dou, J.W., Ren, C.C., Hao, Y., Yan, R., Yang, Y.Q., Yanghe Decoction's impact on the expression of CD90 and its antitumor effect in nude mice bearing human breast cancer. World Chin. Med. 03 (2015), 391–393 (+398).
23. Du, J., A Preliminary Study of the Chemical Composition of Carbon Ginger. 2014, Guangdong Pharmaceutical University, Guangdong.
24. Du, S.Y., Li, Q.L., Yu, J., Determination of Sinapine cyanide sulfonate in white Mustard seed by RP HPLC. J. China Pharm. 27 (2007), 2126–2128.
25. Ellis, M., Overcoming endocrine therapy resistance by signal transduction inhibition. Oncologist 9:Suppl 3 (2004), 20–26.
26. Ellis, M.J., Ding, L., Shen, D., Luo, J., Suman, V.J., Wallis, J.W., Van Tine, B.A., Hoog, J., Goiffon, R.J., Goldstein, T.C., Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486 (2012), 353–360, 10.1038/nature11143.
27. Ellis, M.J., Coop, A., Singh, B., Mauriac, L., Llombert-Cussac, A., Jänicke, F., Miller, W.R., Evans, D.B., Dugan, M., Brady, C., Quebe-Fehling, E., Borgs, M., Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and /or ErbB-2-positive, estrogen receptor- positive primary breast cancer; evidence from a phase III randomized trial. J. Clin. Oncol. 19 (2001), 3808–3816.
28. Feng, B.M., Yu, Z.J., Li, F., Yang, A.G., Liu, J.D., Mou, H.M., Hua, H.M., Wang, Q., Study on the chemical constituents of Sinapis seeds. J. Dali. Univ. 25 (2004), 43–44.
29. Foley, J., Nickerson, N.K., Nam, S., Allen, K.T., Gilmore, J.L., Nephew, K.P., Riese, D.J. 2nd, EGFR signaling in breast cancer: bad to the bone. Semin. Cell Dev. Biol. 21 (2010), 951–960, 10.1016/j.semcdb.2010.08.009.
30. Fox, E.M., Bernaciak, T.M., Wen, J., Weaver, A.M., Shupnik, M.A., Silva, C.M., Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells. Mol. Endocrinol. 22 (2008), 1781–1796, 10.1210/me.2007-0419.
31. Fox, E.M., Davis, R.J., Shupnik, M.A., ERbeta in breast cancer—Onlooker, passive player, or active protector. Steroids 73 (2008), 1039–1051, 10.1016/j.steroids.2008.04.006.
32. Fuqua, S.A., Schiff, R., Parra, I., Friedrichs, W.E., Su, J.L., McKee, D.D., Slentz-Kesler, K., Moore, L.B., Willson, T.M., Moore, J.T., Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer. Cancer Res. 59 (1999), 5425–5428.
33. Gao, X.Y., Wang, W.Q., Wei, S.L., Li, W.D., Review of pharmacological effects of Glycyrrhiza Radix and its bioactive compounds. J. Chin. Mater. Med. 21 (2009), 2695–2700.
34. Goldhirsch, A., Winer, E.P., Coates, A.S., Gelber, R.D., Piccart-Gebhart, M., Thürlimann, B., Senn, H.J., Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International expert consensus on the primary therapy of early breast cancer. Ann. Oncol. 24 (2014), 2206–2223.
35. Gong, C., Li, S.H., Jia, W.J., Su, F.X., Study on the effects of survival rate by using adjuvant chemother apy including paclitaxel on patients with HER-2 positive br east cancer. Lingnan Mod. Clin. Surg. 06 (2006), 436–437 (+441).
36. Gonzalez-Angulo, A.M., Morales-Vasquez, F., Hortobagyi, G.N., Overview of resistance to systemic therapy in patients with breast cancer. Adv. Exp. Med. Biol. 608 (2007), 1–22, 10.1007/978-0-387-74039-3_1.
37. Gradishar, W.J., Anderson, B.O., Blair, S.L., Burstein, H.J., Cyr, A., Elias, A.D., Farrar, W.B., Forero, A., Giordano, S.H., Goldstein, L.J., Hayes, D.F., Hudis, C.A., Isakoff, S.J., Ljung, B.M., Marcom, P.K., Mayer, I.A., McCormick, B., Miller, R.S., Pegram, M., Pierce, L.J., Reed, E.C., Salerno, K.E., Schwartzberg, L.S., Smith, M.L., Soliman, H., Somlo, G., Ward, J.H., Wolff, A.C., Zellars, R., Shead, D.A., Kumar, R., National comprehensive cancer network breast cancer panel. (Breast cancer version 3.2014) J. Natl. Compr. Cancer Netw. 12 (2014), 542–590.
38. Guille, A., Chaffanet, M., Birnbaum, D., Signaling pathway switch in breast cancer. Cancer Cell Int., 13, 2013, 66, 10.1186/1475-2867-13-66.
39. Hamosh, A., Scott, A.F., Amberger, J.S., Bocchini, C.A., McKusick, V.A., Online Mendelian inheritance in man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res. 33 (2005), D514–D517.
40. Hanstein, B., Djahansouzi, S., Dall, P., Beckmann, M.W., Bender, H.G., Insights into the molecular biology of the estrogen receptor define novel therapeutic targets for breast cancer. Eur. J. Endocrinol. 150 (2004), 243–255.
41. Hatkevich, T., Ramos, J., Santos-Sanchez, I., Patel, Y.M., A naringenin-tamoxifen combination impairs cell proliferation and survival of MCF-7 breast cancer cells. Exp. Cell Res. 327 (2014), 331–339, 10.1016/j.yexcr.2014.05.017.
42. Hopkins, A.L., Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 4 (2008), 682–690.
43. Hou, X.Y., Wu, C., Zhou, Y.T., Deng, X.J., Yin, X.Y., Xue, Z.Y., Liao, Q.F., Cai, H., Sun, X.M., Liu, G.H., Zhang, L., Study on contents and distribution of four active components in different parts of Cinnamomum Cassia Presl. Mod. Tradit. Chin. Med. Mater. Med.— World Sci. Technol. 02 (2013), 254–259.
44. Hsu, Y.L., Wu, L.Y., Hou, M.F., Tsai, E.M., Lee, J.N., Liang, H.L., Jong, Y.J., Hung, C.H., Kuo, P.L., Glabridin, an isoflavan from licorice root, inhibits migration, invasion and angiogenesis of MDA-MB-231 human breast adenocarcinoma cells by inhibiting focal adhesion kinase/Rho signaling pathway. Mol. Nutr. Food Res. 55 (2011), 318–327, 10.1002/mnfr.201000148.
45. Hu, G.X., Zhang, C.H., Zhao, W.N., Yu, Q.S., QSPR study on the permeability of drugs across Caco-2 monolayer. J. Zhejiang Univ. 3 (2009), 304–308.
46. Huang, D.W., Sherman, B.T., Lempicki, R.A., Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4 (2009), 44–57.
47. Im, N.K., Jang, W.J., Jeong, C.H., Jeong, G.S., Delphinidin suppresses PMA-induced MMP-9 expression by blocking the NF-κB activation through MAPK signaling pathways in MCF-7 human breast carcinoma cells. J. Med. Food 17 (2014), 855–861, 10.1089/jmf.2013.3077.
48. Joensuu, H., Kellokumpu Lehtinen, P.L., Bono, P., Alanko, T., Kataja, V., Asola, R., Utriainen, T., Kokko, R., Hemminki, A., Tarkkanen, M., Turpeenniemi-Hujanen, T., Jyrkkiö, S., Flander, M., Helle, L., Ingalsuo, S., Johansson, K., Jääskeläinen, A.S., Pajunen, M., Rauhala, M., Kaleva-Kerola, J., Salminen, T., Leinonen, M., Elomaa, I., Isola, J., FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 354 (2006), 809–820.
49. Kang, H.Y., Wang, Y.M., Du, G.J., Lin, H.H., Promotion of Yanghe Decoction-containg serum for inhibitory Effect of doxorubicin on MCF-7 cell and the related mechanism. Chin. J. Exp. Tradit. Med. Formul. 18 (2011), 196–199.
50. Kang, Y., Siegel, P.M., Shu, W., Drobnjak, M., Kakonen, S.M., Cordón-Cardo, C., Guise, T.A., Massagué, J., A multigenic program mediating breast cancer metastasis to bone. Cancer cell 3 (2003), 537–549.
51. Kim, M.J., Ro, J.Y., Ahn, S.H., Kim, H.H., Kim, S.B., Gong, G., Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum. Pathol. 37 (2006), 1217–1226.
52. Koboldt, D.C., Fulton, R.S., McLellan, M.D., Schmidt, H., Kalicki-Veizer, J., McMichael, J.F., Fulton, L.L., Dooling, D.J., Ding, L., Mardis, E.R., Wilson, R.K., et al., The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490 (2012), 61–70, 10.1038/nature11412.
53. Kurebayashi, J., Current clinical trials of endocrine therapy for breast cancer. Breast Cancer 14 (2007), 200–214.
54. Li, C., Zhao, Y., Yang, D., Yu, Y., Guo, H., Zhao, Z., Zhang, B., Yin, X., Inhibitory effects of kaempferol on the invasion of human breast carcinoma cells by downregulating the expression and activity of matrix metalloproteinase-9. Biochem. Cell Biol. 93 (2015), 16–27, 10.1139/bcb-2014-0067.
55. Li, H.W., Meng, X.L., Research progress on chemical constituents and pharmacological activities of Rehmannia glutinosa. Drug Eval. Res. 02 (2015), 218–228.
56. Li, J.W., Liu, X.F., Chen, H.Z., Chen, H.H., Shi, G.X., Wang, S.J., Effect of yanghe huayan decoction on precancerosis of breast cancer, protein and mRNA expression of ki67: an experimental research. Chin. J. Integr. Trad. West. Med. 34 (2014), 970–975.
57. Li, Y., Zhao, H., Wang, Y., Zheng, H., Yu, W., Chai, H., Zhang, J., Falck, J.R., Guo, A.M., Yue, J., Peng, R., Yang, J., Isoliquiritigenin induces growth inhibition and apoptosis through downregulating arachidonic acid metabolic network and the deactivation of PI3K/Akt in human breast cancer. Toxicol. Appl. Pharmacol. 272 (2013), 37–48, 10.1016/j.taap.2013.05.031.
58. Li, Y.W., Zhu, G.Y., Shen, X.L., Chu, J.H., Yu, Z.L., Fong, W.F., Furanodienone induces cell cycle arrest and apoptosis by suppressing EGFR/HER2 signaling in HER2-overexpressing human breast cancer cells. Cancer Chemother. Pharm. 68 (2011), 1315–1323, 10.1007/s00280-011-1624-x.
59. Li, Z.H., Xie, Y.W., Gong, Y., Lei, Q.M., Analysis of short-term efficacy of taxane based neoadjuvant chemotherapy in HER-2 positive breast cancer. Chin. J. Breast Dis. 03 (2012), 272–278.
60. Liang, W., Yew, D.T., Hon, K.L., Wong, C.K., Kwok, T.C., Leung, P.C., Indispensable value of clinical trials in the modernization of traditional Chinese medicine: 12 years' experience at CUHK and future perspectives. Am. J. Chin. Med. 42 (2014), 587–604.
61. Liu, X., Ouyang, S., Yu, B., Liu, Y., Huang, K., Gong, J., Zheng, S., Li, Z., Li, H., Jiang, H., PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach. Nucleic Acids Res. 38 (2010), W609–W614.
62. Liu, Y.F., Study on Reactive Substance and Function of Rehmannia. 2013, Peking Union Medical College, Beijing.
63. Liu, Y.X., Tian, J., Study on The effects of inhibiting proliferation of rat's medicament blood serum of YH decoction on human breast cancer cell MCF-7 ER(+) and MDA-MB-231 ER(-). Chin. Arch. Tradit. Chin. Med 02 (2009), 243–246.
64. Lu, D.P., Wang, Y., Progress of pharmacological action and clinical application of Rehmannia. Strait Pharm. J. 03 (2004), 23–26.
65. Margueron, R., Duong, V., Castet, A., Cavaillès, V., Histone deacetylase inhibition and estrogen signalling in human breast cancer cells. Biochem. Pharmacol. 68 (2004), 1239–1246.
66. McCubrey, J.A., Steelman, L.S., Abrams, S.L., Lee, J.T., Chang, F., Bertrand, F.E., Navolanic, P.M., Terrian, D.M., Franklin, R.A., D'Assoro, A.B., Salisbury, J.L., Mazzarino, M.C., Stivala, F., Libra, M., Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv. Enzym. Regul. 46 (2006), 249–279.
67. Metodiewa, D., Kochman, A., Karolczak, S., Evidence for antiradical and antioxidant properties of four biologically active N,N-Diethylaminoethyl ethers of flavaone oximes: a comparison with natural polyphenolic flavonoid rutin action. IUBMB Life 41 (1997), 1067–1075.
68. Missiuro, P.V., Liu, K., Zou, L., Ross, B.C., Zhao, G., Liu, J.S., Ge, H., Information flow analysis of interactome networks. PLoS Comput. Biol., 5, 2009, e1000350, 10.1371/journal.pcbi.1000350.
69. Mylona, E., Alexandrou, P., Mpakali, A., Giannopoulou, I., Liapis, G., Markaki, S., Keramopoulos, A., Nakopoulou, L., Clinicopathological and prognostic significance of vascular endothelial growth factors （VEGF）-C and -D and VEGF receptor 3 in invasive breast carcinoma. Eur. J. Surg. Oncol. 33 (2007), 294–300.
70. Oesterreich, S., Zhang, P., Guler, R.L., Sun, X., Curran, E.M., Welshons, W.V., Osborne, C.K., Lee, A.V., Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth. Cancer Res. 61 (2001), 5771–5777.
71. Orchard, S., Ammari, M., Aranda, B., Breuza, B., Briganti, L., Broackes-Carter, L., Campbell, F., Chavali, N.H., Chen, G., del-Toro, C., Duesbury, N., Dumousseau, M., Galeota, M., Hinz, E., Iannuccelli, U., Jagannathan, M., Jimenez, S., Khadake, R., Lagreid, J., Licata, A., Lovering, L., Meldal, R.C., Melidoni, B., Milagros, A.N., Peluso, M., Perfetto, D., Porras, L., Raghunath, P., Ricard-Blum, A., Roechert, S., Stutz, B., Tognolli, A., van Roey, M., Cesareni, K., Hermjakob, H, G., The MIntAct project—intact as a common curation platform for 11 molecular interaction databases. Nucleic Acids Res. 42 (2014), D358–D363.
72. Ozbay, T., Nahta, R., Delphinidin inhibits HER2 and Erk1/2 signaling and suppresses growth of HER2-overexpressing and triple negative breast cancer cell lines. Breast Cancer 25 (2011), 143–154, 10.4137/BCBCR.S7156.
73. Pan, C.Y., Bai, B., Wu, Y., Notch signal pathway and breast cancer. ABER 2 (2014), 5–9.
74. Perou, C.M., Sorlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, C.A., Pollack, J.R., Ross, D.T., Johnsen, H., Akslen, L.A., Fluge, O., Pergamenschikov, A., Williams, C., Zhu, S.X., Lønning, P.E., Børresen-Dale, A.L., Brown, P.O., Botstein, D., Molecular portraits of human breast tumours. Nature 406 (2000), 747–752.
75. Piccart Gebhart, M.J., Procter, M., Leyland Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., Cameron, D., Dowsett, M., Barrios, C.H., Steger, G., Huang, C.S., Andersson, M., Inbar, M., Lichinitser, M., Láng, I., Nitz, U., Iwata, H., Thomssen, C., Lohrisch, C., Suter, T.M., Rüschoff, J., Suto, T., Greatorex, V., Ward, C., Straehle, C., McFadden, E., Dolci, M.S., Gelber, R.D., Herceptin Adjuvant (HERA) (Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER-2-positive breast cancer. N. Engl. J. Med., 353, 2005, 1659.
76. Piek, E., Moustakas, A., Kurisaki, A., Heldin, C.H., ten Dijke, P., TGF-(beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. J. Cell Sci. 112 (1999), 4557–4568.
77. Qiu, R.J., Prospective Cohort Study of HER-2 Positive Breast Cancer Treated by TCM Differentiation Syndromes Therapy. 2013, China Academy Chinese medical Science, Beijing.
78. Rivera Rivera, A., Castillo-Pichardo, L., Gerena, Y., Dharmawardhane S1.anti-breast cancer potential of Quercetin via the Akt/AMPK/mammalian target of Rapamycin (mTOR) signaling cascade. PLoS One, 11, 2016, e0157251, 10.1371/journal.pone.0157251.
79. Romond, E.H., Perez, E.A., Bryant, J., Suman, V.J., Geyer, C.E. Jr., Davidson, N.E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P.A., Swain, S.M., Pisansky, T.M., Fehrenbacher, L., Kutteh, L.A., Vogel, V.G., Visscher, D.W., Yothers, G., Jenkins, R.B., Brown, A.M., Dakhil, S.R., Mamounas, E.P., Lingle, W.L., Klein, P.M., Ingle, J.N., Wolmark, N., Trastuzumab plus adjuvant chemotherapyfor operable HER-2-positive breast cancer. N Engl J Med, 353(16), 2005, 1673.
80. Ru, J., Li, P., Wang, J., Zhou, W., Li, B., Huang, C., Huang, C., Li, P., Guo, Z., Tao, W., Yang, Y., Xu, X., Li, Y., Wang, Y., Yang, L., TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J. Cheminform., 6, 2014, 13.
81. van der Schaft, D.W., Pauwels, P., Hulsmans, S., Zimmermann, M., van de Poll-Franse, L.V., Griffioen, A.W., Absence of lymphangiogenesis in ductal breast cancer at the primary tumor site. Cancer Lett. 254 (2007), 128–136.
82. Schneeweiss, A., Ruckhäberle, E., Huober, J., Chemotherapy for metastatic breast cancer - An Anachronism in the era of personalised and targeted oncological therapy?. Geburtshilfe Frauenheilkd. 75 (2015), 574–583.
83. Shah, S.P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486 (2012), 395–399, 10.1038/nature10933.
84. Sharma, G., Kar, S., Palit, S., Das, P.K., 18β-glycyrrhetinic acid induces apoptosis through modulation of Akt/FOXO3a/Bim pathway in human breast cancer MCF-7 cells. J. Cell Physiol. 227 (2012), 1923–1931, 10.1002/jcp.22920.
85. Siegel, P.M., Shu, W., Cardiff, R.D., Muller, W.J., Massagué, J., Transforming growth factor β signaling impairs neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc. Natl. Acad. Sci. USA, 100, 2003, 84308435.
86. Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016. CA Cancer J. Clin. 66 (2016), 7–30.
87. Skildum, A., Faivre, E., Lange, C.A., Progesterone receptors induce cell cycle progression via activation of mitogen-activated protein kinases. Mol. Endocrinol. 19 (2005), 327–339.
88. Song, R.X., Zhang, Z., Chen, Y., Bao, Y., Santen, R.J., Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells. Endocrinology 148 (2007), 4091–4101.
89. Sørlie, T., Perou, C.M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Thorsen, T., Quist, H., Matese, J.C., Brown, P.O., Botstein, D., Lønning, P.E., Børresen-Dale, A.L., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 98 (2001), 10869–10874, 10.1073/pnas.191367098.
90. Sotiriou, C., Neo, S.Y., McShane, L.M., Korn, E.L., Long, P.M., Jazaeri, A., Martiat, P., Fox, S.B., Harris, A.L., Liu, E.T., Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl. Acad. Sci. USA 100 (2003), 10393–10398, 10.1073/pnas.1732912100.
91. Sui, J.Q., Xie, K.P., Xie, M.J., Inhibitory effect of luteolin on the proliferation of human breast cancer cell lines induced by epidermal growth factor. Sheng Li Xue Bao 68 (2016), 27–34.
92. Sumida, T., Itahana, Y., Hamakawa, H., Desprez, P.Y., Reduction of human metastatic breast cancer cell aggressiveness on introduction of either form a or B of the progesterone receptor and then treatment with progestins. Cancer Res. 64 (2004), 7886–7892.
93. Sun, X., Zhang, X., Nian, J.Y., Guo, J., Yin, Y., Zhang, G.L., Yu, M.W., Zhang, Y., Wang, X.M., Yang, G.W., Yang, L., Cheng, P.Y., Li, J.P., Chinese herbal medicine as adjunctive therapy to chemotherapy for breast cancer: a systematic review and meta-analysis. Evid. Based Complement Altern. Med., 2016, 2016, 3281968, 10.1155/2016/3281968 (Epub 2016 Apr 10).
94. Swiatoniowski, G., Dabrowska, M., Kłaniewski, T., Molenda, W., Erb-2 overexpression in breast cancer. Ginekol. Pol. 74 (2003), 332–338.
95. Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., Simonovic, M., Roth, A., Santos, A., Tsafou, K.P., Kuhn, M., Bork, P., Jensen, L.J., von Mering, C., STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 43 (2015), D447–D452.
96. Tang, H., He, S., Zhang, X., Luo, S., Zhang, B., Duan, X., Zhang, Z., Wang, W., Wang, Y., Sun, Y., A network pharmacology approach to uncover the pharmacological mechanism of XuanHuSuo powder on osteoarthritis. Evid. Based Complement Altern. Med., 2016, 2016, 3246946, 10.1155/2016/3246946.
97. Tao, J.J., Visvanathan, K., Wolff, A.C., Long term side effects of adjuvant chemotherapy in patients with early breast cancer. Breast 24:Suppl. 2 (2015), S149–S153, 10.1016/j.breast.2015.07.035.
98. Tao, S.F., He, H.F., Chen, Q., Quercetin inhibits proliferation and invasion acts by up-regulating miR-146a in human breast cancer cells. Mol. Cell Biochem. 402 (2015), 93–100, 10.1007/s11010-014-2317-7.
99. Taylor, M.A., Parvani, J.G., Schiemann, W.P., The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells. J. Mammary Gland Biol. Neoplasia 15 (2010), 169–190, 10.1007/s10911-010-9181-1.
100. Tian, J., Experimental Studies on Confidence Test of Yang He Decoction Treat Breast Cancer. 2008, Hebei Medical University, Hebei.
101. Tian, Q.L., Guan, Y.P., Zhang, B., Liu, H.Z., Research advances on pharmacological activities of components in licorice. Nat. Prod. Res. Dev. 02 (2006), 343–347.
102. Tobias, J.S., Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women. Int. J. Biochem. Cell. Biol. 36 (2004), 2112–2119.
103. Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., Jemal, A., Global cancer statistics, 2012. CA Cancer J. Clin. 65 (2015), 87–108, 10.3322/caac.21262.
104. Valcourt, U., Kowanetz, M., Niimi, H., Heldin, C.H., Moustakas, A., TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. Mol. Biol. Cell 16 (2005), 1987–2002.
105. Walters, W.P., Murcko, M.A., Prediction of ‘drug-likeness'. Adv. Drug Deliv. Rev. 54 (2002), 255–271.
106. Wang, K.L., Hsia, S.M., Chan, C.J., Chang, F.Y., Huang, C.Y., Bau, D.T., Wang, P.S., Inhibitory effects of isoliquiritigenin on the migration and invasion of human breast cancer cells. Expert. Opin. Ther. Targets 17 (2013), 337–349, 10.1517/14728222.2013.756869.
107. Wang, X.F., Zhou, Q.M., Lu, Y.Y., Zhang, H., Huang, S., Su, S.B., Glycyrrhetinic acid potently suppresses breast cancer invasion and metastasis by impairing the p38 MAPK-AP1 signaling axis. Expert. Opin. Ther. Targets 19 (2015), 577–587, 10.1517/14728222.2015.1012156.
108. Wang, Z., Wang, N., Han, S., Wang, D., Mo, S., Yu, L., Huang, H., Tsui, K., Shen, J., Chen, J., Dietary compound isoliquiritigenin inhibits breast cancer neoangiogenesis via VEGF/VEGFR-2 signaling pathway. PLoS One, 8, 2013, e68566, 10.1371/journal.pone.0068566.
109. Weldon, C.B., Elliott, S., Zhu, Y., Clayton, J.L., Curiel, T.J., Jaffe, B.M., Burow, M.E., Regulation of estrogen-mediated cell survival and proliferation by p160 coactivators. Surgery 136 (2004), 346–354.
110. Worster, D.T., Schmelzle, T., Solimini, N.L., Lightcap, E.S., Millard, B., Mills, G.B., Brugge, J.S., Albeck, J.G., Akt and ERK control the proliferative response of mammary epithelial cells to the growth factors IGF-1 and EGF through the cell cycle inhibitor p57Kip2. Sci. Signal, 5, 2012, 10.1126/scisignal.2001986.
111. Wu, X.Y., Xu, H., Wu, Z.F., Chen, C., Liu, J.Y., Wu, G.N., Yao, X.Q., Liu, F.K., Li, G., Shen, L., Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models. Oncotarget 6 (2015), 44563–44578, 10.18632/oncotarget.6310.
112. Xu, X., Zhang, W., Huang, C., Li, Y., Yu, H., Wang, Y., Duan, J., Ling, Y., A novel chemometric method for the prediction of human oral bioavailability. Int. J. Mol. Sci. 13 (2012), 6964–6982.
113. Yang, M.Y., Wang, C.J., Chen, N.F., Ho, W.H., Lu, F.J., Tseng, T.H., Luteolin enhances paclitaxel-induced apoptosis in human breast cancer MDA-MB-231 cells by blocking STAT3. Chem. Biol. Interact. 213 (2014), 60–68, 10.1016/j.cbi.2014.02.002.
114. You, L., An, R., Liang, K., Wang, X., Anti-breast cancer agents from Chinese herbal medicines. Mini Rev. Med. Chem. 13 (2013), 101–105, 10.2174/138955713804484785.
115. Zhang, F., Dong, W., Zeng, W., Zhang, L., Zhang, C., Qiu, Y., Wang, L., Yin, X., Zhang, C., Liang, W., Naringenin prevents TGF-β1 secretion from breast cancer and suppresses pulmonary metastasis by inhibiting PKC activation. Breast Cancer Res., 18, 2016, 8, 10.1186/s13058-016-0698-0.
116. Zhao, W., Studies on the Chemical Constituents of Ephedra Sinica. 2009, Peking Union Medical College, Beijing.
117. Zhao, X., Wang, Q., Yang, S., Chen, C., Li, X., Liu, J., Zou, Z., Cai, D., Quercetin inhibits angiogenesis by targeting calcineurin in the xenograft model of human breast cancer. Eur. J. Pharmacol. 781 (2016), 60–68, 10.1016/j.ejphar.2016.03.063.
118. Zhou, F.Y., Li, T., Liu, L., Xu, D.S., HPLC fingerprints of amino acids constituents in Cervil Cornus Colla. Chin. J. Exp. Tradit. Med. Formul. 09 (2014), 47–51.
119. Zhou, J., Zhou, T., Jiang, M., Wang, X., Liu, Q., Zhan, Z., Zhang, X., Research progress on synergistic anti-tumor mechanisms of compounds in Traditional Chinese Medicine. J. Tradit. Chin. Med. 34 (2014), 100–105.
120. Zhou, R., Xu, L., Ye, M., Liao, M., Du, H., Chen, H., Formononetin inhibits migration and invasion of MDA-MB-231 and 4T1 breast cancer cells by suppressing MMP-2 and MMP-9 through PI3K/AKT signaling pathways. Horm. Metab. Res. 46 (2014), 753–760, 10.1055/s-0034-1376977.
121. Zhu, L., Li, L., Li, Y., Wang, J., Wang, Q., Chinese herbal medicine as an adjunctive therapy for breast cancer: a systematic review and meta-analysis. Evid. Based Complement Altern. Med., 2016, 2016, 9469276, 10.1155/2016/9469276 (Epub 2016 May 9).
122. Zhu, X.D., Correlating signal transduction pathway of mammary epithelial stem cells to breast cancer. CRTER 21 (2008), 4151–4154.